HP
PGNX

Hikari Power’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Hikari Power’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,302
Closed -$52K – 128
2018
Q4 		$52K Sell
12,302
-87,698
-88% -$447K 0.01% 123
2018
Q3 		$627K Sell
100,000
-100,000
-50% -$768K 0.06% 74
2018
Q2 		$1.61M Hold
200,000
– – 0.18% 59
2018
Q1 		$1.49M Hold
200,000
– – 0.18% 54
2017
Q4 		$1.19M Hold
200,000
– – 0.14% 57
2017
Q3 		$1.47M Buy
+200,000
New +$1.27M 0.19% 51

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Hikari Power's PGNX Position: Q1 2019 in Review

Hikari Power sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 12,302 shares — an estimated $52K sold.

Hikari Power first reported a position in PGNX in Q3 2017 and held it in 6 quarters. The position peaked at $1.61M in Q2 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Hikari Power reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Hikari Power sold 12,302 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $52K.
  • Hikari Power first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 6 quarters.
  • Hikari Power's Progenics Pharmaceuticals Inc position peaked at $1.61M in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Hikari Power's 13F filing for Q1 2019, filed 26 Apr 2019.